Literature DB >> 19156411

Nuclear imaging in cardiac amyloidosis.

A W J M Glaudemans1, R H J A Slart, C J Zeebregts, N C Veltman, R A Tio, B P C Hazenberg, R A J O Dierckx.   

Abstract

Amyloidosis is a disease characterized by depositions of amyloid in organs and tissues. It can be localized (in just one organ) or systemic. Cardiac amyloidosis is a debilitating disease and can lead to arrhythmias, deterioration of heart function and even sudden death. We reviewed PubMed/Medline, without time constraints, on the different nuclear imaging modalities that are used to visualize myocardial amyloid involvement. Several SPECT tracers have been used for this purpose. The results with these tracers in the evaluation of myocardial amyloidosis and their mechanisms of action are described. Most clinical evidence was found for the use of (123)I-MIBG. Myocardial defects in MIBG activity seem to correlate well with impaired cardiac sympathetic nerve endings due to amyloid deposits. (123)I-MIBG is an attractive option for objective evaluation of cardiac sympathetic level and may play an important role in the indirect measurement of the effect of amyloid myocardial infiltration. Other, less sensitive, options are (99m)Tc-aprotinin for imaging amyloid deposits and perhaps (99m)Tc-labelled phosphate derivatives, especially in the differential diagnosis of the aetiology of cardiac amyloidosis. PET tracers, despite the advantage of absolute quantification and higher resolution, are not yet well evaluated for the study of cardiac amyloidosis. Because of these advantages, there is still the need for further research in this field.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156411     DOI: 10.1007/s00259-008-1037-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  80 in total

1.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

2.  Radionuclide angiographic assessment of left ventricular diastolic filling in amyloid heart disease: a study of patients with familial amyloid polyneuropathy.

Authors:  M Hongo; T Fujii; J Hirayama; O Kinoshita; M Tanaka; S Okubo
Journal:  J Am Coll Cardiol       Date:  1989-01       Impact factor: 24.094

3.  Usefulness of technetium pyrophosphate scintigraphy in demonstrating cardiac amyloidosis in persons aged 85 years and older.

Authors:  S A Goldstein; J Lindsay; P L Chandeysson; N G Nolan
Journal:  Am J Cardiol       Date:  1989-03-15       Impact factor: 2.778

4.  Indium-111 antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection.

Authors:  I Carrió; L Berná; M Ballester; M Estorch; D Obrador; M Cladellas; L Abadal; M Ginjaume
Journal:  J Nucl Med       Date:  1988-12       Impact factor: 10.057

5.  Scanning for soft-tissue amyloid.

Authors:  R W Kula; W K Engel; B R Line
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

6.  Symptomatic cardiac amyloidosis in an American family.

Authors:  M A Ruder; M A Alpert; J F Sanfelippo; J D Dix; R B Whiting
Journal:  South Med J       Date:  1984-07       Impact factor: 0.954

7.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

Review 8.  Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis.

Authors:  Per Westermark; Merrill D Benson; Joel N Buxbaum; Alan S Cohen; Blas Frangione; Shu-Ichi Ikeda; Colin L Masters; Giampaolo Merlini; Maria J Saraiva; Jean D Sipe
Journal:  Amyloid       Date:  2005-03       Impact factor: 7.141

9.  99mTc-aprotinin scintigraphy in amyloidosis.

Authors:  Bente K Schaadt; Helle W Hendel; Peter Gimsing; Viggo Jønsson; Heidi Pedersen; Birger Hesse
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

10.  Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection.

Authors:  V W Lee; A G Caldarone; R H Falk; A Rubinow; A S Cohen
Journal:  Radiology       Date:  1983-07       Impact factor: 11.105

View more
  22 in total

Review 1.  Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review.

Authors:  Adam Castaño; Sabahat Bokhari; Thomas H Brannagan; Julia Wynn; Mathew S Maurer
Journal:  Amyloid       Date:  2011-12-08       Impact factor: 7.141

2.  Imaging Findings and Literature Review of (18)F-FDG PET/CT in Primary Systemic AL Amyloidosis.

Authors:  Joo Hee Lee; Ga Yeon Lee; Seok Jin Kim; Ki Hyun Kim; Eun-Seok Jeon; Kyung-Han Lee; Byung-Tae Kim; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2015-05-13

3.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

Review 4.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

5.  Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software.

Authors:  Tanja Kero; Lars Lindsjö; Jens Sörensen; Mark Lubberink
Journal:  J Nucl Cardiol       Date:  2015-07-15       Impact factor: 5.952

6.  In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Sallie Macy; Emily B Martin; Angela Williams; Keiichi Higuchi; Stephen J Kennel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

7.  Pursuing an underdiagnosed disease: a simple imaging test for increasing suspicion of cardiac amyloidosis.

Authors:  Rodney H Falk; Sharmila Dorbala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03       Impact factor: 9.236

8.  Cardiac amyloidosis: evolving approach to diagnosis and management.

Authors:  Hans K Meier-Ewert; Vaishali Sanchorawala; John L Berk; Frederick L Ruberg
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

9.  The role of nuclear cardiac imaging in risk stratification of sudden cardiac death.

Authors:  Daniel Juneau; Fernanda Erthal; Benjamin J W Chow; Calum Redpath; Terrence D Ruddy; Juhani Knuuti; Rob S Beanlands
Journal:  J Nucl Cardiol       Date:  2016-07-28       Impact factor: 5.952

Review 10.  Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques.

Authors:  Wael A Aljaroudi; Milind Y Desai; W H Wilson Tang; Dermot Phelan; Manuel D Cerqueira; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2014-04       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.